One of the parameters that define the therapeutic potential of an antibiotic is its ability to kill the pathogen ([@r1][@r2]--[@r3]). Bacteriostatic drugs stop bacteria from growing but do not prevent them from resuming proliferation once the inhibitor is removed. In contrast, only few cells, if any, can resume growth upon treatment with bactericidal antibiotics. While cidality is related to the mode of antibiotic action, even inhibitors of the same class can differ significantly in their ability to kill bacteria ([@r4]), a concept particularly applicable to macrolide antibiotics ([@r5]).

Macrolides inhibit protein synthesis and bacterial growth by binding in the nascent peptide exit tunnel (NPET) of the ribosome ([@r6]) ([Fig. 1](#fig01){ref-type="fig"}). While many macrolides, e.g., erythromycin (ERY), are largely bacteriostatic ([@r7], [@r8]), drugs of later generations, e.g., solithromycin (SOL), exhibit a more pronounced bactericidal activity ([@r5], [@r9]). We recently showed that the cidal capacity of macrolides depends on their dissociation kinetics from the ribosome ([@r10]). The faster dissociating macrolides tend to be bacteriostatic, whereas the slower dissociating ones are considerably more bactericidal. Importantly, the rate of dissociation from the ribosome and the cidality of the macrolides critically depend on the presence of an extended alkyl-aryl side chain in the antibiotic structure ([@r10]) ([Fig. 1](#fig01){ref-type="fig"}).

![The binding site of macrolides in the ribosome. A cross-section of the *E. coli* ribosome showing ERY (PDB ID code 4V7U) ([@r11]) and SOL (PDB ID code 4WWW) ([@r12]) bound in the nascent peptide exit tunnel. The zoomed-in image shows the interaction of the alky-aryl side chain (boxed) of SOL with the A752-U2609 base pair.](pnas.1918948117fig01){#fig01}

Crystallographic studies showed that in the nontranslating *Escherichia coli* ribosome the macrolide side chain may interact with a putative 23S ribosomal RNA (rRNA) base pair formed by residues A752 and U2609 belonging to the distant domains II and V, respectively ([@r11], [@r12]) ([Fig. 1](#fig01){ref-type="fig"}). However, both of these residues are partially accessible for modifications by chemical reagents that target single-stranded RNA ([@r13][@r14]--[@r15]), and it remains unknown whether this base pair forms in a ribosome that is engaged in protein synthesis. Residues A752 and U2609 were rendered unpaired in the initial crystallographic structures of the vacant *E. coli* ribosome ([@r16]) but were presented in base-paired configuration in later reconstructions of the ribosome complexed with macrolides ([@r11], [@r12]). In the structures of ribosomes from other bacteria, these residues have been rendered unpaired, partially paired, or fully paired ([@r17][@r18][@r19]--[@r20]). Irrespective of the interaction status assigned on the basis of static crystallographic structures, the existence of the A752-U2609 base pair in the translating ribosome, its importance for macrolide binding, and its contribution to the mode of antibiotic action have not been established with any certainty.

Here, we demonstrate that in the translating ribosome the distant residues A752 and U2609 likely form a base pair, which contributes to nascent peptide sensing. We show that this long-range base pair is critical for the dissociation kinetics and cidality of macrolides with extended side chains, likely due to specific interactions between this base pair and the drug. Our finding may guide a strategy for developing new macrolides with improved bactericidal properties through optimization of the idiosyncratic interactions with the ribosome.

Results and Discussion {#s1}
======================

Disruption of the A752-U2609 Base Pair Affects the Ribosomal Response to Regulatory Nascent Peptides. {#s2}
-----------------------------------------------------------------------------------------------------

We engineered two *E. coli* strains to carry the single mutations A752G or U2609C that would partially or completely disrupt the putative base pair, and a third strain where mutations A752G and U2609C were introduced simultaneously to restore the base-pairing potential. Because in the engineered strains the rRNA is exclusively expressed from a plasmid ([@r21]), the cells contain pure populations of mutant ribosomes.

The doubling time of all three mutants in rich media was practically indistinguishable from that of the WT cells (τ ∼ 32 min), and the in vitro activity of the isolated wt and mutant ribosomes was comparable ([Fig. 2*A*](#fig02){ref-type="fig"}). Thus, neither the identity of the 23S rRNA residues 752 or 2609, nor their potential to form a base pair, is critical for cell growth or for general ribosomal functions.

![Role of the 752-2609 base pair in ribosomal activities. (*A*) In vitro translation of the sf-GFP protein by WT and mutant ribosomes monitored by fluorescence. Error bars represent SD of three independent experiments. (*B*) Toeprinting analysis of the SecM-mediated programmed ribosome stalling during translation of the *secM* gene by WT and mutant ribosomes. Bands representing SecM-arrested ribosomes (Pro codon in the A site) are marked by a red arrowhead. Reactions in lanes 6--9 contained indolmycin, an inhibitor of tryptophanyl-tRNA synthetase, which leads to trapping ribosomes at the Trp codon (gray arrowhead) prior to the *secM* programmed arrest site. The comparable intensity of the trap-site bands shows that the general translation of *secM* is not affected by the ribosomal mutations. (*C*) The bar graph showing relative intensity of the *secM* arrest bands in samples 2--5. Error bars represent SEM of two independent experiments.](pnas.1918948117fig02){#fig02}

Since nucleotides A752 and U2609 are located in the NPET, where they likely interact with growing proteins, we wondered whether they could play a role in the ribosomal response to regulatory nascent peptides ([@r22]). Indeed, disruption of the A752-U2609 base pair decreases the efficiency of translational arrest mediated by SecM ([Fig. 2*B*](#fig02){ref-type="fig"}, lanes 3 and 4), a nascent peptide involved in sensing secretion stress ([@r23]). Remarkably, SecM-mediated stalling was reduced in single mutants but was restored in the A752G/U2609C double mutant ([Fig. 2*B*](#fig02){ref-type="fig"}, lane 5). These findings parallel the previous observation that the integrity of the 752-2609 base pair is important for ribosome stalling during translation of the regulatory leader peptide TnaC of the tryptophanase operon ([@r24]). Altogether, our data argue that the A752-U2609 base pair does form in the translating ribosome, facilitating the response to nascent peptides.

The Ribosomes with an Intact or Disrupted 752-2609 Base Pair Bind Macrolides with Comparable Affinities. {#s3}
--------------------------------------------------------------------------------------------------------

Because crystallographic studies have indicated that the alkyl-aryl side chain of macrolides can interact with the paired A752/U2609 nucleotides ([@r11], [@r17]) ([Fig. 1](#fig01){ref-type="fig"}), it was suggested that disruption of this base pair would decrease the affinity of the drug for the ribosome ([@r11]). However, equilibrium binding of SOL to the ribosome was minimally affected by the mutations ([Fig. 3*A*](#fig03){ref-type="fig"}). Hence, varying the identities of the 23S rRNA residues 752 and 2609 or disrupting their base-pairing capacity does not impact the macrolides overall affinity for the ribosome.

![Effect of the 752-2609 base pair on the interactions of macrolides with the ribosome. (*A*) Equilibrium binding of SOL. Ribosomes were equilibrated for 2 h with varying \[^14^C\]-SOL concentrations and then the amount of bound antibiotic was measured ([@r10]). *K*~D~ values determined from the binding curves are indicated. SOL (*B*) and ERY (*C*) dissociation kinetics. Following preequilibration of ribosomes with \[^14^C\]-SOL (*B*) or \[^14^C\]-ERY (*C*), an excess of the corresponding unlabeled antibiotic was added, and ribosome-associated radioactivity was monitored over time. Error bars represent SD of three independent replicates.](pnas.1918948117fig03){#fig03}

The Integrity of the A752-U2609 Base Pair Slows the Departure of the Extended Macrolides from the Ribosome. {#s4}
-----------------------------------------------------------------------------------------------------------

To further characterize the interactions between macrolides and ribosomes with or without the A752G/U2609C base pair, we measured the rate of antibiotic dissociation. Consistent with our previous data ([@r10]), SOL slowly dissociates from WT ribosomes with biphasic kinetics, likely reflecting the existence of fast and slowly dissociating ribosome--drug complexes ([Fig. 3*B*](#fig03){ref-type="fig"} and [Table 1](#t01){ref-type="table"}). Similar kinetic was observed for the mutant ribosomes with the restored A752G/U2609C base pair ([Fig. 3*B*](#fig03){ref-type="fig"} and [Table 1](#t01){ref-type="table"}). In contrast, the single A752G or U2609C mutations accelerated the SOL off rate in both the fast-dissociating and slow-dissociating populations. In addition, the fast-dissociating population became predominant, leading to an overall significantly expedited departure of SOL from the ribosome ([Fig. 3*B*](#fig03){ref-type="fig"} and [Table 1](#t01){ref-type="table"}). Unlike their effect on dissociation kinetics of SOL, these mutations had only a minor influence on the monophasic dissociation kinetics of ERY ([Fig. 3*C*](#fig03){ref-type="fig"} and [Table 1](#t01){ref-type="table"}), a drug that lacks the alkyl-aryl side chain ([Fig. 1](#fig01){ref-type="fig"}). These data suggest that the effect of the 752-2609 base pair on the rate of drug dissociation from the ribosome is specifically mediated by the interaction established with the macrolide side chain.

###### 

Kinetic parameters of dissociation of ERY and SOL from WT or mutant *E. coli* ribosomes

  Mutation(s)      ERY[\*](#tfn1){ref-type="table-fn"}   SOL[^†^](#tfn2){ref-type="table-fn"}                     
  ---------------- ------------------------------------- -------------------------------------- ----------------- -------------
  WT(A752/U2609)   0.32 ± 0.020                          0.063 ± 0.018                          0.0036 ± 0.0008   42.7 ± 6.3
  U2609C           0.15 ± 0.015                          0.120 ± 0.019                          0.0085 ± 0.0002   69.1 ± 5.4
  A752G            0.13 ± 0.010                          0.089 ± 0.020                          0.0101 ± 0.0002   53.1 ± 8.2
  A752G/U2609C     0.36 ± 0.023                          0.063 ± 0.045                          0.0050 ± 0.0001   26.9 ± 11.2

The single rate constants for ERY were estimated from the dissociation curves shown in [Fig. 3*C*](#fig03){ref-type="fig"}.

The fast and slow rate dissociation constants for SOL were obtained by fitting the data of the curves shown in [Fig. 3*B*](#fig03){ref-type="fig"} to double-exponential functions.

Disruption of the 752-2609 Base Pair Alleviates Macrolide Cidality. {#s5}
-------------------------------------------------------------------

We asked whether disrupting the ability of 752-2609 nucleotides to base pair would also interfere with the cidality of the extended macrolides. First, we determined the minimal inhibitory concentration (MIC) of SOL and found that neither the individual A752G or U2609C, nor the compensatory A752G/U2609C mutations had any pronounced effect on the sensitivity to the drug (MIC~SOL~ = 0.25--0.5 µg/mL). \[Of note, the previously reported 4- to 8-fold resistance of the U2609C mutant to the extended macrolides ([@r15]) was observed only in strains with the intact *tolC* gene, whereas it was not manifested in the Δ*tolC* cells used in the present experiments.\]

Having established that the rRNA mutations do not affect MIC~SOL~ in our strains, we examined the survival of the WT and mutant cells after their exposure to SOL. When exposed to high concentrations of SOL, only ∼0.01% of the cells with the 752-2609 base pair could resume growth whereas, in contrast, ∼10 times more cells survived the equivalent antibiotic treatment when the 752-2609 base pair was weakened or disrupted by the single mutations ([Fig. 4*A*](#fig04){ref-type="fig"}). The same trend was observed when cells were exposed for varying time intervals to a fourfold MIC of SOL ([Fig. 4*B*](#fig04){ref-type="fig"}). This result shows that the integrity of the 752-2609 base pair defines not only the dynamics of the interaction between the drug and the ribosome but also the bactericidal activity of the drug against *E. coli*. The mutations had only minimal effect on cidality of the side chain-lacking ERY ([Fig. 4*C*](#fig04){ref-type="fig"}).

![The base pairing ability of the 23S rRNA residues 752 and 2609 impacts the bactericidal properties of SOL. (*A*) Concentration dependence of SOL cidality after 4 h drug exposure. (*B*) Time dependence of the cidal effect of 4× MIC of SOL. (*C*) Cell survival after 4 h treatment with 7× MIC of ERY (gray bars) or SOL (black bars). Error bars represent SD of three independent replicates.](pnas.1918948117fig04){#fig04}

Although in ∼95% of analyzed bacterial genomes the identities of the 23S rRNA residues 752 and 2609 (*E. coli* numbering) support the base pair formation, the pairing ability is not universal ([@r25]). Nevertheless, macrolides with extended side chain can exhibit cidality even against some bacteria lacking the base pair ([@r26]). This agrees well with our data showing that although the disruption of the 752-2609 base pair reduced SOL cidality, this antibiotic still killed the mutant cells more readily than ERY, which lacks the alkyl-aryl side chain ([Fig. 4*C*](#fig04){ref-type="fig"}). Conceivably, when the 752-2609 base pair cannot be formed, the macrolide\'s extended side chain may maintain stacking interaction with one of the unpaired bases or, alternatively, may reorient and interact with other nearby rRNA residues ([@r20], [@r27]). It is also possible that even in the species where pairing of the 23S rRNA residues 752 and 2609 can occur, the base pair may form only transiently in response to additional cues, e.g., the presence of a nascent protein with a specific amino acid sequence in the NPET or the binding of specific small molecules, including the extended-chain macrolides ([@r6]). The dynamic nature of this base pair could account for the biphasic kinetics of SOL dissociation from the *E. coli* ribosomes observed in our experiments ([Fig. 3*B*](#fig03){ref-type="fig"}), as well as biphasic binding mode of extended macrolides reported previously ([@r28]), where the off and on rates of the antibiotic could depend on the formation or disruption of the pairing of the 752 and 2609 residues.

Although our experiments have been carried out only with SOL, we expect that similar effects would be observed with other extended macrolide antibiotics, e.g., telithromycin, whose alkyl-aryl side chain establishes equivalent interactions with the A752-U2609 base pair ([@r11], [@r12]). Altogether, our findings suggest that optimizing the interactions with the A752-U2609 base pair by modifying the side chain of macrolides or other drugs binding in a similar ribosomal location could be a strategy to improve the antibiotics cidal activity.

Materials and Methods {#s6}
=====================

Construction of Mutant Strains. {#s7}
-------------------------------

Single A752G or U2609C or double A752G/U2609C mutations were introduced by site-directed mutagenesis into 23S rRNA gene of the pAM552 plasmid ([@r29]) using the QuikChange Lightning Multi Site-directed mutagenesis kit (Agilent Technologies). Plasmids were transformed into the Δ*tolC E. coli* SQ171 strain lacking chromosomal rRNA alleles ([@r21], [@r30]), and transformants were cured off the resident pCSacB plasmid encoding WT rRNA ([@r31]). The presence of the mutation and the purity of the ribosome population carrying the mutant rRNA was verified by sequencing and by primer extension on the total cellular rRNA.

Ribosome Preparation and Binding Studies. {#s8}
-----------------------------------------

WT and mutant ribosomes were purified according to ref. [@r32]. Equilibrium and kinetic binding studies were performed as described in ref. [@r10].

In Vitro Translation and Toeprinting. {#s9}
-------------------------------------

Translation and toeprinting reactions were carried out in the Δribosome PURExpress system (New England Biolabs) supplemented with isolated WT or mutant ribosomes as described in ref. [@r29]. Plasmid pY71-sfGFP ([@r33]) was used as a template for translation of sfGFP reporter protein. Expression of sfGFP was continuously monitored by fluorescence (488~ex~/520~em~ nm) in a microplate reader (Tecan). Toeprinting analysis was carried out as described in ref. [@r34] using a DNA template prepared by PCR encoding the last 29 codons of the *secM* gene.

MIC Determination and Cidality Testing. {#s10}
---------------------------------------

MIC was determined in 96-well plates by serial dilution of antibiotic and incubating plates overnight at 37 °C without shaking. The optical density of the starting bacterial cultures was *A*~600~ = 0.001. For the analyses of bactericidal action, overnight cultures were diluted 1:500 and grown at 37 °C to *A*~600~ ∼ 0.2. Various concentrations of SOL or ERY were added and culture dilutions were plated after 4 h incubation. For the time-kill measurements, cells were incubated with 4× MIC~SOL~ (2 µg/mL for WT, A752G, and A752G/U2609C mutants, 1 µg/mL for U2609C mutant). Aliquots were withdrawn, and culture dilutions were plated. Colonies were counted following 48- to 72-h incubation at 37 °C. For comparison of SOL and ERY cidality, cells were incubated for 4 h with 7× MIC concentrations of the drugs: SOL (3.5 µg/mL for WT, A752G, and A752G/U2609C mutants, 1.75 µg/mL for U2609C mutant); ERY (7 µg/mL for WT, A752G, and A752G/U2609C mutants, 3.5 µg/mL for U2609C mutant).

Data Availability. {#s11}
------------------

The engineered strains are available upon request.
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